A Failing Flaw in Traditional Clinical Trial Design and How RWE Can Help
Diversity in clinical trial populations is critical for adequately assessing the safety and efficacy of new therapies in all patient populations. However, a recent study that compared diversity across randomized clinical trials, the SEER national cancer registry database, and real-world evidence studies, showed that age, ethnicity, and gender are most reflective of the general patient population in real-world evidence studies as compared to randomized clinical trials.1
With these new findings, it is clear the use of real-world evidence is key for increasing diversity in the scientific study of treatments. Join industry experts for this important one-hour discussion to learn more and explore:
- The current barriers to diversity of age, gender, race and ethnicity in clinical trials
- A deeper dive into the recent study findings comparing RCT, SEER, and RWE
- What these findings mean for RWE and health equity moving forward
1. "Comparison of Patient Demographics in Oncologic Randomized Controlled Trials (RCTs) with Real-World Data (RWD) and the Surveillance, Epidemiology, and End Results (SEER) U.S. Population Registry"